AUSTIN, Texas; Oct. 25, 2022 (Business Wire) – Elligo Health Research®, the ultimate healthcare-enabling research organization, has focused on growing clinical research participation, but today reported that the company has also grown consistently and significantly over the past few years, both in revenue and scale.
Founded just over five years ago, the Austin, Texas-based Elligo just won the Fast 50 Award, sponsored by the Austin Business Journal, distinguishing them as one of the top 50 private companies in central Texas showing impressive net revenue growth of over 100% from 2019 to 2021.
“There is a huge demand for accelerating clinical research study execution by trial sponsors and a strong desire in healthcare to help patients access clinical trials,” said Elligo CEO John Potthoff, Ph.D. “Since Elligo’s strategy centers on both, this has enabled rapid growth so we can continue increasing participation in clinical trials — the ultimate goal.”
Elligo is among many technology companies in Austin, which has become the secondary office location for some of the world’s largest technology companies. While based in Texas, Elligo has locations and employees all around the globe. Elligo significantly increased its scale of operations over the past year by acquiring Root Health, an AI virtual assistant for clinical research; raised $135 million in Series E funding, which enabled joining in a major expansion with ClinEdge; and launched European operations via a collaboration with WHYZE Health.
“This rapid growth is possible from relationships and partnerships, many of which are new this past year,” said Elligo Chief Commercial Officer Brandon Cormier. “Our dedicated employee team also played a major role. Elligo grew from 80 to 500 since 2016, and we anticipate doubling over the next year — hiring an additional 100 to 150 to continue making needed changes to the clinical research landscape.”
About Elligo Health Research®
Elligo Health Research accelerates clinical trials through healthcare with access to over 150 million known patients and their HIPAA-compliant healthcare data, our IntElligo® Research Stack technology, and our PatientSelect identification and engagement model. Coupled with the largest Known Patient Access Network, Elligo’s Site Solutions enable healthcare practices and research sites to participate in clinical trials. By adaptive engagement of known patients and physicians, we accelerate the development of new pharmaceutical, biotechnology, and medical device and diagnostic products.